> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Juno Scraps CAR-T Cell Product Development
- URL: https://www.fdaweb.com/juno-scraps-car-t-cell-product-development/
- Published: 2017-03-02T12:00:00.000Z
- Updated: 2026-09-14T22:09:36.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5138114

Juno Therapeutics says it is ceasing development of its CAR-T cell product candidate JCAR015, indicated for relapsed or refractory B cell acute lymphoblastic leukemia (r/r ALL) due to a greater than expected incidence of severe neurotoxicity and five deaths from cerebral edema were observed last year. The product was placed on clinical hold late last year as a result of the adverse events ([see story](https://www.fdaweb.com/juno-setback-on-car-t-cell-product-after-another-trial-mishap/)).

  
“Through the investigation Juno identified multiple factors that may have contributed to this increased risk, including patient-specific factors, the conditioning chemotherapy patients received, and factors related to the product,” the company says. “Although Juno believes there are protocol modifications and process improvements that could enable Juno to proceed with JCAR015 in clinical testing in adult r/r ALL, Juno would first need to establish preliminary safety and dose in a Phase 1 trial. As a result of the timing delay that would entail and Juno’s belief that it has other product candidates in its pipeline that are likely to provide improved efficacy and tolerability, Juno, in collaboration with partner Celgene, has made a strategic decision to cease development of JCAR015 at this time and to redirect associated resources to the development of a defined cell product candidate in the adult r/r ALL setting.”